GLP1R and hydrops fetalis: A systematic review and meta-analysis of RCTs revealed that GLP-1 receptor agonists reduced MACE by 14% and also reduced all-cause mortality by 12%, hospital admission for HF by 11%, and the composite kidney outcome by 21%, with no increase in risk of severe hypoglycemia, retinopathy, or pancreatic adverse effects [73].